| Oct 3 |
Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program
|
| Sep 30 |
Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer
|
| Sep 26 |
Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024
|
| Sep 4 |
Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024
|
| Aug 30 |
Abercrombie upgraded, Dollar General downgraded: Wall Street's top analyst calls
|
| Aug 28 |
Trevi Therapeutics to Participate in September Investor and Medical Conferences
|
| Aug 11 |
Trevi Therapeutics, Inc. (TRVI) Q2 2024 Earnings Call Transcript
|
| Aug 9 |
Trevi Therapeutics GAAP EPS of -$0.12
|
| Aug 8 |
Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance
|
| Aug 7 |
Institutional investors in Trevi Therapeutics, Inc. (NASDAQ:TRVI) see US$40m decrease in market cap last week, although long-term gains have benefitted them.
|
